<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588470</url>
  </required_header>
  <id_info>
    <org_study_id>MM20060280</org_study_id>
    <secondary_id>T001</secondary_id>
    <nct_id>NCT01588470</nct_id>
  </id_info>
  <brief_title>Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) - Role of Intramyocellular Lipid Content and Mitochondrial Dysfunction in Myocardial Insulin Resistance and Their Correction With Pioglitazone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the existence of heart abnormalities in patients with
      diabetes and the effect of pioglitazone in correcting these abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES

        1. To quantitate myocardial insulin sensitivity using positron emission tomography (PET)
           with 18F-deoxyglucose in type 2 diabetes mellitus (T2DM) and control subjects.

        2. To quantitate pericardial fat using magnetic resonance spectroscopy in T2DM and control
           subjects.

        3. To quantitate cardiac function using magnetic resonance imaging and echocardiography in
           T2DM and control subjects.

        4. To examine the effect of pioglitazone on myocardial insulin sensitivity, pericardial fat
           content, and cardiac function.

      SECONDARY OBJECTIVES To examine the relationships between myocardial insulin sensitivity,
      pericardial fat content, and cardiac function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>this study includes single arm intervention with pioglitazone. T2DM individuals will be studied at baseline and after 6 months treatment.
as a reference group, healthy subjects will be studied in cross sectional fashion. Because healthy subjects will not be treated nor restudied at 6 months, they can not be considered a separate arm in the study but rather a reference group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in E to A Ratio</measure>
    <time_frame>Baseline and 6-months Post Treatment</time_frame>
    <description>The E to A ratio is a marker of the function of the left ventricle of the heart. It represents the ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by the atrial contraction (the A wave) This is measured using ultrasound-based cardiac imaging. In a healthy heart the E velocity is greater than the A velocity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Glucose Uptake</measure>
    <time_frame>Baseline and 6-months Post Treatment</time_frame>
    <description>Measurement of change in myocardial glucose uptake from baseline to 6 months of treatment with pitoglitazone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c</measure>
    <time_frame>Baseline and 6-months Post Treatment</time_frame>
    <description>Change in hemoglobin A1c levels measured at 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>45 mg per day for 6 months</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to communicate meaningfully with the investigator and must be
             legally competent to provide written informed consent.

          -  Patients may be of either sex. Female patients must be non-lactating and must either
             be at least one year post-menopausal, or be using adequate contraceptive precautions
             (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm
             with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral
             tubal ligation, bilateral oophorectomy). Female patients who have undergone a
             hysterectomy are eligible for participation in the study. Female patients (except for
             those patients who have undergone a hysterectomy or a bilateral oophorectomy) are
             eligible only if they have a negative pregnancy test throughout the study period

          -  Patients must range in age from 18 to 75 years, inclusive.

          -  Patients with type 2 diabetes must be drug naïve, receiving monotherapy with metformin
             or with a sulfonylurea, or combination therapy with both: metformin &amp; sulfonylurea.

          -  Patients must have the following laboratory values:

               -  Hematocrit ≥ 34 vol%

               -  Serum creatinine ≤ 1.8 mg/dl

               -  AST (SGOT) ≤ 2.5 times upper limit of normal

               -  ALT (SGPT) ≤ 2.5 times upper limit of normal

               -  Alkaline phosphatase ≤ 2 times upper limit of normal

          -  Patients must have been on a stable dose of allowed chronic medications for 30 days
             prior to entering the study.

          -  Only subjects whose body weight has been stable (±3-4 pounds) over the three months
             prior to study will be included.

        Exclusion Criteria:

          -  Patients must not have type 1 diabetes.

          -  Patients must not be receiving any medications with known adverse effects on glucose
             tolerance (except metformin or a sulfonylurea) unless the patient has been on stable
             doses of such agents for the past three months before entry into the study. Patients
             may be taking stable doses of estrogens or other hormonal replacement therapy, if the
             patient has been on these agents for the prior three months. Patients taking systemic
             glucocorticoids are excluded.

          -  Patients with a history of clinically significant heart disease (New York Heart
             Classification greater than class 2; more than non-specific ST-T wave changes on the
             EKG), peripheral vascular disease (history of claudication), or pulmonary disease
             (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation)
             will not be studied.

          -  Patients with hematocrit &lt; 34% will be excluded.

          -  Patient who were exposed to any procedure involves radiation exposure and his total
             radiation dose equivalent exceeds 5 rem during the past year will be excluded from the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <results_first_submitted>February 17, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2017</results_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ralph DeFronzo</investigator_full_name>
    <investigator_title>Professor &amp; Division Chief, Department of Medicine, Division of Diabetes</investigator_title>
  </responsible_party>
  <keyword>diastolic function</keyword>
  <keyword>mitochondria</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>pericardial fat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD data will not be available for other researchers. However, a manuscript describing the study results is under review for publication in the medical literature</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
pioglitazone : 45 mg per day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130">First enrolled April 2007</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50">Completed Dec. 2011</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
pioglitazone: 45 mg per day for 6 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in E to A Ratio</title>
        <description>The E to A ratio is a marker of the function of the left ventricle of the heart. It represents the ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by the atrial contraction (the A wave) This is measured using ultrasound-based cardiac imaging. In a healthy heart the E velocity is greater than the A velocity.</description>
        <time_frame>Baseline and 6-months Post Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Measure of E to A Ratio to determine which subjects will receive
pioglitazone: 45 mg per day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>E to A Ratio After Pioglitazone Treatment</title>
            <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
pioglitazone: 45 mg per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in E to A Ratio</title>
          <description>The E to A ratio is a marker of the function of the left ventricle of the heart. It represents the ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by the atrial contraction (the A wave) This is measured using ultrasound-based cardiac imaging. In a healthy heart the E velocity is greater than the A velocity.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.28"/>
                    <measurement group_id="O2" value="1.25" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Glucose Uptake</title>
        <description>Measurement of change in myocardial glucose uptake from baseline to 6 months of treatment with pitoglitazone</description>
        <time_frame>Baseline and 6-months Post Treatment</time_frame>
        <population>Study participants who met eligibility criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease measurement of Myocardial Glucose Uptake (MGU) at before Pioglitazone administration.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Subjects with T2DM or non-diabetic subjects with coronary heart disease who received Pioglitazone -45 mg per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Glucose Uptake</title>
          <description>Measurement of change in myocardial glucose uptake from baseline to 6 months of treatment with pitoglitazone</description>
          <population>Study participants who met eligibility criteria</population>
          <units>uM/min/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.14"/>
                    <measurement group_id="O2" value="0.42" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c</title>
        <description>Change in hemoglobin A1c levels measured at 6 months</description>
        <time_frame>Baseline and 6-months Post Treatment</time_frame>
        <population>Enrolled subjects that meet eligibility criteria as type 2 diabetics or non diabetic subjects with coronary heart disease</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
pioglitazone: 45 mg per day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
pioglitazone: 45 mg per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c</title>
          <description>Change in hemoglobin A1c levels measured at 6 months</description>
          <population>Enrolled subjects that meet eligibility criteria as type 2 diabetics or non diabetic subjects with coronary heart disease</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="1.3"/>
                    <measurement group_id="O2" value="5.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>data were collected over 6 months period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
pioglitazone: 45 mg per day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Mild weight gain ~2kg with ankle edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Muhammad Abdul-Ghani, MD</name_or_title>
      <organization>UT Health Science, San Antonio</organization>
      <phone>210-567-6691</phone>
      <email>abdulghani@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

